Application of astragaloside in preparation of medicine for preventing Alzheimer's disease

A technology of Alzheimer's disease and astragaloside, which is applied in the field of biomedicine, can solve the problems that have not been fully studied, and achieve the effect of broadening the selection field, increasing the expression level, and inhibiting hypermethylation

Pending Publication Date: 2022-05-13
GANSU HEBO LONG PHARMA TECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether astragalosides can be a natural drug for preventing Alzheimer's disease has not been fully studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astragaloside in preparation of medicine for preventing Alzheimer's disease
  • Application of astragaloside in preparation of medicine for preventing Alzheimer's disease
  • Application of astragaloside in preparation of medicine for preventing Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0024] The preparation of relevant reagent in the embodiment is as follows:

[0025] 1. Preparation of Aβ oligomers

[0026] 1mg of Aβ 1-42 Powder (AnaSpec), fully dissolved with 222 μL pre-cooled hexafluoroisopropanol (HFIP, sigma) and shaken to mix well, let stand at room temperature for 60 minutes, and place on ice for 10 minutes to obtain 1mmoL / L Aβ 1-42 solution. Vacuum dry the volatile HFIP until clear Aβ is produced at the bottom of the EP tube 1-42 -HFIP-peptide film, long-term storage at -80°C. Take out the peptide film before use, add 44μL DMSO and mix well to make 5mM Aβ 1-42 mother liquor. Add 2156 μL of pre-cooled PBS to make 100 μmoL / L of Aβ 1-42 working fluid. Incubate at 4°C for 24h, centrifuge at 4°C / 14000x g for 10min, discard the precipitate and absorb the supernatant, filter through a filter, and obtain Aβ 1-42 Oligomers, aliquoted and stored at -80°C.

[0027] 2. Memantine configuration

[0028] Weigh 10 mg memantine hydrochloride (sigma) and dis...

Embodiment 1

[0032] CCK8 detects primary neuronal viability

[0033] CCK-8 reagent (Cell Counting Kit-8 cell counting reagent) contains WST-8: chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl) -5-(2,4-disulfonic acid benzene)-2H-tetrazole monosodium salt, its role in the electron carrier 1-methoxy-5-methylphenazine dimethyl sulfate (1-Methoxy PMS) It is reduced to a highly water-soluble yellow formazan product (Formazan) by the dehydrogenase in the mitochondria of the cell, and the amount of the generated formazan is proportional to the number of living cells. The light absorption value was measured at a wavelength of 450nm by an enzyme-linked immunosorbent assay instrument, which can indirectly reflect the number of living cells. This method has been widely used in the activity detection of some biologically active factors, large-scale antitumor drug screening, cell proliferation test, cytotoxicity test and drug sensitivity test, etc.

[0034] Test materials: 3d SD rats (purc...

Embodiment 2

[0040] Immunofluorescence staining

[0041] Immunofluorescence technique (Immunofluorescence technique) is a technique established on the basis of immunology, biochemistry and microscopy techniques. This technique utilizes antigen-antibody reactions to localize antigenic substances in tissues or cells.

[0042] Test materials: 3d SD rats (purchased from Lanzhou University Experimental Animal Center), Anti-MAP2antibody, 488 fluorescent antibody, sheep serum, PBS, fetal bovine serum, horse serum, B27 medium, penicillin and streptomycin, astragaloside.

[0043] The specific experimental steps are as follows:

[0044] Divide the primary neurons into 5 groups, respectively marked as C, D, Aβ, AS, and Memantine, and inoculate them on glass slides in polylysine-coated 24-well plates, and grow the cells to a density of 70%-80% , and completely adhered to the wall, group C did not receive any treatment; group D was treated with a solvent of DMSO:PBS=1:49; group Aβ was added with Aβ ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of astragaloside in preparation of a medicine for preventing Alzheimer's disease. The astragaloside can be astragaloside, an available salt of the astragaloside, a solvate of the astragaloside or an astragaloside derivative. The astragaloside can promote the growth of neurons, improve the expression quantity of NMDAR-CREB signal channel related proteins, inhibit histone hypermethylation, relieve cognitive impairment and achieve the effect of preventing the Alzheimer's disease.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the use of astragaloside in the preparation of drugs for preventing Alzheimer's disease. Background technique [0002] Alzheimer's disease (AD) is a progressive neurodegenerative disease. Epigenetic dysregulation, which results in altered gene expression in the brain, is thought to be one of the key pathophysiological underpinnings of Alzheimer's disease. Repressive histone H3 dimethylation at lysine 9 (H3K9me2) is markedly elevated in a mouse model of advanced familial Alzheimer's disease (FAD), consistent with attenuated transcription, expression, and function of NMDA receptors It is related to and will eventually lead to clinical features such as cognitive impairment and learning and memory impairment. With the aggravation of the degree of aging in our country, AD has become the culprit affecting the health of the elderly. Therefore, effective prevention and treatment of AD has b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K36/481A61P25/28
CPCA61K31/7048A61K36/481A61P25/28
Inventor 邵宝平丁艳平马昕刘欣姜辰昕汪迁昊
Owner GANSU HEBO LONG PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap